Marcus Stahlman
Overview
Explore the profile of Marcus Stahlman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
5705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis
Kocyigit D, Zimetti F, Gurses K, Zanotti I, Marchi C, Stahlman M, et al.
Atheroscler Plus
. 2023 Jan;
44:18-24.
PMID: 36644669
Background And Aims: Cholesterol efflux capacity is a functional property of high-density lipoproteins (HDL) reflecting the efficiency of the atheroprotective reverse cholesterol transport process in humans. Its relationship with calcific...
2.
Fuchs C, Dixon E, Hendrikx T, Mlitz V, Wahlstrom A, Stahlman M, et al.
Hepatol Commun
. 2022 Jun;
6(9):2368-2378.
PMID: 35691019
Bile salt export pump (Bsep) (Abcb11) mice are protected from acquired cholestatic injury due to metabolic preconditioning with a hydrophilic bile acid (BA) pool with formation of tetrahydroxylated bile acids...
3.
van Son J, Serlie M, Stahlman M, Backhed F, Nieuwdorp M, Aron-Wisnewsky J
Nutrients
. 2021 Aug;
13(8).
PMID: 34444866
Background: The gut microbiota and its metabolites are essential for host health and dysbiosis has been involved in several pathologic conditions such as type 2 diabetes (T2D) and cardiovascular disease...
4.
Caputo M, Cansby E, Kumari S, Kurhe Y, Nair S, Stahlman M, et al.
Hepatol Commun
. 2021 Jul;
5(7):1183-1200.
PMID: 34278168
Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of chronic liver disease worldwide, primarily because of the massive global increase in obesity. Despite intense research efforts in...
5.
Behr A, Kwiatkowski A, Stahlman M, Schmidt F, Luckert C, Braeuning A, et al.
Arch Toxicol
. 2021 Jun;
95(8):2891.
PMID: 34189593
No abstract available.
6.
Besse L, Besse A, Stolze S, Sobh A, Zaal E, van der Ham A, et al.
Cancer Res
. 2021 Jun;
81(17):4581-4593.
PMID: 34158378
The HIV-protease inhibitor nelfinavir has shown broad anticancer activity in various preclinical and clinical contexts. In patients with advanced, proteasome inhibitor (PI)-refractory multiple myeloma, nelfinavir-based therapy resulted in 65% partial...
7.
Choi B, Daniel N, Houde V, Ouellette A, Marcotte B, Varin T, et al.
Nat Commun
. 2021 Jun;
12(1):3377.
PMID: 34099716
Animal models of human diseases are classically fed purified diets that contain casein as the unique protein source. We show that provision of a mixed protein source mirroring that found...
8.
Caputo M, Kurhe Y, Kumari S, Cansby E, Amrutkar M, Scandalis E, et al.
FASEB J
. 2021 Apr;
35(5):e21567.
PMID: 33891332
Nonalcoholic fatty liver disease (NAFLD) is emerging as a leading cause of chronic liver disease worldwide. Despite intensive nonclinical and clinical research in this field, no specific pharmacological therapy is...
9.
Keipert S, Lutter D, Schroeder B, Brandt D, Stahlman M, Schwarzmayr T, et al.
Nat Commun
. 2021 Mar;
12(1):1804.
PMID: 33727559
No abstract available.
10.
Kocyigit D, Tokgozoglu L, Gurses K, Stahlman M, Boren J, Soyal M, et al.
Acta Cardiol
. 2020 Dec;
76(5):544-552.
PMID: 33334254
Background: Histopathological changes in calcific aortic stenosis (CAS) resemble changes in coronary atherosclerosis. Concerning recent evidence on dietary and gut microbiota-related metabolites representing players in atherosclerosis, we aimed to investigate...